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To analyze serum immunoglobulin G (IgG) antibodies to major isoforms of myelin oligo-
dendrocyte glycoprotein (MOG-alpha 1-3 and beta 1-3) in patients with inflammatory de-
myelinating diseases.
Methods
Retrospective case-control study using 378 serum samples from patients with multiple sclerosis
(MS), patients with non-MS demyelinating disease, and healthy controls with MOG alpha-1-
IgG positive (n = 202) or negative serostatus (n = 176). Samples were analyzed for their
reactivity to human, mouse, and rat MOG isoforms with and without mutations in the extra-
cellular MOG Ig domain (MOG-ecIgD), soluble MOG-ecIgD, and myelin from multiple
species using live cell-based, tissue immunofluorescence assays and ELISA.
Results
The strongest IgG reactivities were directed against the longest MOG isoforms alpha-1 (the
currently used standard test for MOG-IgG) and beta-1, whereas the other isoforms were less
frequently recognized. Using principal component analysis, we identified 3 different binding
patterns associated with non-MS disease: (1) isolated reactivity toMOG-alpha-1/beta-1 (n = 73),
(2) binding to MOG-alpha-1/beta-1 and at least one other alpha, but no beta isoform (n = 64),
and (3) reactivity to all 6 MOG isoforms (n = 65). The remaining samples were negative
(n = 176) for MOG-IgG. These MOG isoform binding patterns were associated with a non-MS
demyelinating disease, but there were no differences in clinical phenotypes or disease course. The
3 MOG isoform patterns had distinct immunologic characteristics such as differential binding to
soluble MOG-ecIgD, sensitivity to MOG mutations, and binding to human MOG in ELISA.
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Conclusions
The novel finding of differential MOG isoform binding patterns could inform future studies on the refinement of MOG-IgG
assays and the pathophysiologic role of MOG-IgG.
Serum immunoglobulinG (IgG) autoantibodies against myelin
oligodendrocyte glycoprotein (MOG-IgG) are associated with
a spectrum of neurologic diseases including optic neuritis
(ON), acute disseminated encephalomyelitis (ADEM), mye-
litis, seizures, encephalitis, and with brainstem and/or cere-
bellar involvement.1-9 In addition, MOG-IgG appears to be
supportive to discriminate these disorders from multiple scle-
rosis (MS)10,11 as reflected by the first diagnostic recommen-
dations for MOG-IgG–associated disorders (MOGADs).1,6,12
Furthermore, MOGADs are not only characterized by clinical
but also neuropathologic features.13,14
Although most studies use live cell-based assays (CBAs) with
the MOG alpha (α) 1 isoform for the measurement of MOG-
IgG, previous results were often discrepant, because of dif-
ferent MOG expression vectors (full-length vs extracellular
domain), cell lines, read-out systems (immunofluorescence
[IF] vs flow cytometry), and other test variations, which
aimed to increase specificity and eliminate nonspecific low-
titer positivity.1,15-17 Several studies attempted to define the
molecular epitopes of MOG-IgG with the help of amino acid
substitutions or deletions and discovered distinct binding
patterns.18-21 The most frequent epitopes were located in the
loops between the β sheets of the extracellular Ig domain of
human MOG (MOG-ecIgD). These findings were extended
by other studies showing that only a subset of human MOG-
IgG is also reactive to rodent MOG epitopes18,19,22,23 and
pathogenic in vitro or in vivo.19,23,24
Earlier studies using MOG-ecIgD as an antigen for immu-
noassays have indicated a lower sensitivity compared with full-
length MOG (with the α1 isoform as the consensus
sequence).10,25 Although these results indicated binding dif-
ferences to different MOG variants, no study so far has ana-
lyzed antibody responses to different MOG isoforms. Like
most other human myelin genes, the MOG gene undergoes
extensive alternative splicing and multiple different MOG
isoforms have been described in primates, but not in
rodents.26-29 Although the extracellular Ig domain is present
in all these isoforms, they show profound differences in the
composition of the intracellular C terminus resulting in alpha
(α) or beta (β) isoforms.
The aim of our study was to analyze the serum IgG antibody
response to additional MOG isoforms (α2, α3, β1, β2, and β3;
figure 1) in MOGα1-seropositive and MOGα1-seronegative
patients and controls. Furthermore, we analyzed whether the
use of additional MOG isoforms (either alone or in combi-
nations) improves the specificity of MOG-IgG CBAs.
Methods
Patients and Controls
We performed a retrospective case-control study including
serum samples from 378 patients with inflammatory de-
myelinating diseases and healthy controls (HCs) with known
MOG-IgG serostatus recruited from the participating centers
for this study (Innsbruck and Vienna, Austria; Verona, Italy;
Barcelona, Spain; Dublin, Ireland; Oxford, UK; Zurich,
Switzerland; Munich and Lübeck, Germany; and Lyon,
France).2,10,16,22 We included samples from children (age <18
years) and adults (≥18 years) with an aquaporin-4–
seronegative non-MS demyelinating disease typically associ-
ated with MOG-IgG (n = 214, thereof 191 seropositive
MOGAD), MS (n = 64),11 and HCs (n = 100). We also
included MOG-IgG–positive MS (n = 8) and HC (n = 3)
samples collected at different centers, and therefore, MOG-
IgG seropositivity in MS and HCs is overrepresented com-
pared with previous studies. Samples were sent to Innsbruck
and reclassified there as MOG-IgG negative (n = 176; 47%;
MOG-IgG(H + L) titer 0 to 1:80; MOG-IgG(Fc) negative)
or MOG-IgG positive (n = 202; 53%; MOG-IgG(H + L) titer
1:160 to 1:20,480; MOG-IgG(Fc) positive) using a combi-
nation of 2 different live IF MOGα1 CBAs (CBA-IF) as re-
cently described.16 In addition, 106 follow-up samples of 35
individuals were analyzed with a median observation period of
4.1 years (range 0.8–12.1 years). Because a detailed clinical
and radiologic description was not the primary scope of this
study, we summarized clinical data of non-MS patients in
predominant clinical phenotypes: opticospinal (isolated optic
neuritis, myelitis, brainstem syndrome, or a combination of
those, a proportion of these patients fulfilled the current di-
agnostic criteria for neuromyelitis optica spectrum disorder30),
cerebral (ADEM according to current diagnostic criteria,31
Glossary
ADEM = acute disseminated encephalomyelitis; CBA = cell-based assay; FACS = fluorescence-activated cell sorting; HCs =
healthy controls; IF = immunofluorescence;MOG = myelin oligodendrocyte glycoprotein;MOGAD = MOG-IgG–associated
disorders; MOG-ecIgD = extracellular MOG immunoglobulin domain; MOG-IgG = serum IgG antibodies against MOG;
MS = multiple sclerosis;NMOSD = neuromyelitis optica spectrum disorder;ON = optic neuritis; PCA = principal component
analysis.
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multiphasic disseminated encephalomyelitis, brainstem en-
cephalitis, or encephalitis), or a combination of both (ADEM
followed by optic neuritis and opticospinal with cerebral
symptoms) and disease courses (monophasic vs recurrent).
Clinical and demographic data according to the MOG-IgG
serostatus are shown in table e-1, links.lww.com/NXI/A498.
Neuropathologic investigations were available from 6 MOG-
IgG–positive cases: 2 with biopsy and autopsy, 3 with biopsy,
and 1 with autopsy. Four of these patients had previously been
described as case reports and included in a series of patients to
describe the pathology of CNS demyelination accompanied
by MOG-IgG.13 Serum/CSF samples and biopsy/autopsy
specimens were referred to the Division of Neuropathology
and Neurochemistry, Department of Neurology, Medical
University of Vienna for diagnostic purposes and stored at the
institutional biobank.
Standard Protocol Approvals, Registrations,
and Patient Consents
This study was approved by the ethical committees of the
Medical University of Innsbruck, Austria (AM3041A and
AM4059), Medical University of Vienna (EK 1636/2019 and
1123/2015), University of Oxford, UK (REC 16/SC/0224),
Hospital Clinic of Barcelona, Spain (2010/5680), and Uni-
versity of Zürich, Switzerland (KEK ZH 2013-0001). Twenty
serum samples were obtained from the NeuroBioTec—
Hospices Civils de Lyon biobank, 10 samples from the
Neuropathology-Verona biobank, and 10 samples from the
Biobank of LMU Munich, Germany (Biobank 163-16). All
patients or their caregivers and controls gave written informed
consent. All samples from participating centers were anony-
mized before sending them to Innsbruck, Austria.
Cloning of MOG Isoform Constructs
The following human MOG isoforms shown in figure 1 were
expressed as C-terminal enhanced green fluorescent protein fusion
proteins (EGFP) in this study:MOGα1 (NCBI CCDS34370.1;
UniProt Q16653-1), MOGα2 (NCBI CCDS47394.1; UniProt
Q16653-2), MOGα3 (NCBI CCDS34369.1; UniProt Q16653-
3), MOGβ1 (NCBI CCDS4667.1; UniProt Q16653-5),
MOGβ2 (NCBI CCDS34367.1; UniProt Q16653-6), and
MOGβ3 (NCBI CCDS34366.a; UniProt Q16653-7). The
detailed cloning strategies are described in Supplementary
methods. In addition, we used pEGFP-N1 (Takara Clontech)
expression vectors encoding mouse MOG, rat MOG, and the
humanMOGα1mutantsN31Q(N-glycosylation site18,20,21,23,32),
P42S (mouse/rat specific, immunodominant human MOG
Figure 1 Splicing Variants and Protein Isoforms of Human MOG α1-3 and β1-3
(A) Exon composition of different
MOG precursor transcript variants:
leader = signal peptide, removed
during maturation, exon 3 = contains
a stop codon and is present in tran-
scripts for soluble MOG (not depicted
in this schematic), TM = encodes
the single transmembranedomain,M
= encodes the membrane-associated
intracellular part of transcriptsα1 and
β1, exon 7 = specific for transcripts α3
and β3. The last 39 exons encode
specific sequences forMOGα1-3 (10a)
and MOGβ1-3 (10b). (B) Protein iso-
forms of humanMOG α1-3 and β1-3.
The extracellular Ig-like domain is
present in all isoforms (gray), whereas
the specific intracellular composition
is shown slightly enlarged within the
dashedcirclesusing colors fitting to the
coding exons described above. MOG
=myelinoligodendrocyteglycoprotein.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | July 2021 3
epitope18,21,23,32), E64K (possible binding motif for comple-
ment C1q32), A75S (rat specific18,32), R86Q (mouse/rat
specific18,32), and H103A + S104E (epitope of the mouse
monoclonal MOG antibody 8-18-C5, important humanMOG
epitope18,21,23,32,33) as described in Supplementary methods.
Immunoassays for the Detection of MOG-IgG
Binding to Different MOG Isoforms
All live CBAs were performed using HEK293 cells transfected
with the individual expression vectors encoding the different
MOG isoforms described above. Because of the amount of
analyses per sample, evaluation of antibody binding to the
different isoforms and animal species was performed on the
same day to reduce the number of freeze-thawing cycles. All
CBAs (live CBA-IF, live CBA–fluorescence-activated cell
sorting [FACS], and a commercial fixed CBA-IF from Euro-
immun) and ELISAs were performed according to recently
published detailed protocols.16 We used a combination of 2
assays with secondary antibodies to human IgG(H + L) and
confirmation by secondary antibodies to human IgG(Fc) to
exclude isolated IgM reactivity. Final results were given in titer
level (CBA-IF) or binding ratio (CBA-FACS). The binding of
serum samples to human, mouse, and rat myelin was analyzed
by a tissue-based IF assay as described before.19
Competitive Binding Assay Using the Soluble
Extracellular Domain of MOG
We performed competitive binding assays by CBA-FACS16 to
investigate whether MOG-IgG recognizes soluble human
MOG-ecIgD and to determine antibody affinities. Serum
samples were diluted according to their FACSmedian binding
ratio to standardize MOG-IgG amounts. Selection of samples
was based on the MOG isoform binding pattern observed in
live CBA-IF. Diluted serum samples were incubated with in-
creasing amounts (0, 1.6, 3.2, and 9.6 μM) of soluble human
MOG-ecIgD (provided by Euroimmun, Lübeck)16 for 1 hour
at room temperature and spun down at 10,000g for 5 minutes.
After this preabsorption step, samples were analyzed by CBA-
FACS. Nonlinear regression analysis was used to analyze
competitive binding and calculate IC50 values.
Statistical Analysis
The primary hypothesis of this study was that there are dif-
ferential disease-specific IgG antibody responses to MOG
isoforms (α1, α2, α3, β1, β2, and β3). This hypothesis was
tested for antibody titers using the Friedman nonparametric
test, Spearman’s rank nonparametric correlational analyses, and
receiver operating curve analysis. Principal component analysis
(PCA) was used to classify groups of log2-transformed MOG-
IgG titers. This unsupervised, unbiased multivariate analysis
approach was used to identify the set of variables (MOG iso-
forms) accounting for the greatest variation present in the data
set. Loading plots were generated to visualize the combination
ofMOG isoforms responsible for clustering. The analyses of all
secondary and other endpoints focused on estimates (common
OR; positive and negative predictive values [PPV and NPV];
percentages, medians, and median differences) and 95% CI or
25th to 75th interquartile ranges. Groups were compared using
Kruskal-Wallis or χ2 tests. Statistical significance was defined as
2-sided p value < 0.05 (adjusted for multiple comparisons using
Bonferroni’s correction). Statistical analyses were performed
using IBM SPSS software (IBM SPSS Statistics; Version 26.0.
Armonk, NY: IBM Corp.) or GraphPad Prism 9 (GraphPad
Software, La Jolla, CA).
Data Availability
The data set used and analyzed during the current study is
included in the main text or the supplementary files or is
available from the corresponding author on reasonable re-
quest. Expression plasmids for the different isoforms will be
deposited with Addgene.
Results
Differential Antibody Binding toMOG Isoforms
α1, α2, α3, β1, β2, and β3
Because previous studies could not consistently clarify which
MOG epitopes are immunodominant, we used a different ap-
proach and compared the binding of human MOG-IgG with
MOG isoforms α1, α2, α3, β1, β2, and β3. We analyzed serum
samples from 378 individuals with MOG-IgG serostatus de-
termined using MOGα1 live CBA (176 negative and 202 posi-
tive) and single transfections of HEK293 cells with the other
MOG isoforms. Cell surface expression of isoforms was dem-
onstrated by performing live CBA with serial dilutions of the
humanized mouse monoclonal MOG antibody 8-18-C5 show-
ing comparable detection endpoints (figure 2, A and B). Despite
small differences in transfection efficiencies, MOG isoforms
showed comparable specific surface binding of humanizedMOG
antibody 8-18-C5 (figures e-2 and e-3, links.lww.com/NXI/
A498). Therefore, all extracellular domains of the differentMOG
isoforms were determined equally available for antibody binding.
Overall, the strongest antibody reactivities were directed
against the longest MOG isoforms α1 (median titer 1:160,
25th–75th percentile 0–640) and β1 (1:160, 0–640), whereas
isoforms α2 (0, 0–20), α3 (0, 0–80), β2 (0, 0–0), and β3 (0,
0–0) were less frequently recognized (p < 0.001). There were
strong correlations between α1 and β1 (Spearman’s ρ 0.990)
and between α2, α3, β2, and β3 (Spearman’s ρ 0.677–0.845),
whereas the correlations between α1/β1 and α2/α3/β2/β3
were only moderate (Spearman’s ρ 0.427–0.545).
In a next step, we analyzed whether the individual MOG
isoforms are useful for discriminating a non-MS de-
myelinating disease from MS or HC. As can be seen in figure
2C, low-titer antibodies against all MOG isoforms were also
present in a few cases with MS and in HCs. The positive and
negative predictive values for all MOG isoforms according to
titer steps are shown in table e-3, links.lww.com/NXI/A498.
The cutoff values associated with a PPV (for MOG-IgG as-
sociated with a clinical MOGAD phenotype) of ;95% were
≥1:160 for MOG α1 (190/214 non-MS vs 11/164 controls),
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α3 (89/214 non-MS vs 4/164 controls), and β1 (185/214
non-MS vs 10/164 controls), ≥1:40 for MOG α2 (86/214
non-MS vs 5/164 controls) and β2 (52/214 non-MS vs
2/164 controls), and ≥1:80 for MOG β3 (58/214 non-MS vs
2/164 controls).
Identification of Distinct Non-MS–Associated
MOG Isoform Binding Patterns
In a next step, we investigated combinations of MOG iso-
forms using unsupervised PCA to generate a PCA scores plot
of all samples and isoforms (figure 3A). The variables driving
Figure 2 Differential Binding of Human MOG-IgG to MOG Isoforms α1, α2, α3, β1, β2, and β3
(A) Serial dilutions of humanizedmonoclonalmouseMOG antibody 8-18-C5. The graph shows the percentage of 8 replicates determinedMOG-IgG positive in
live CBA-IF transfected with individualMOG isoforms. (B) Mean sensitivity (with 95%) forMOG-IgG in live CBA-IF using the differentMOG isoforms as antigens.
The dashed line indicates the overall mean sensitivity. (C) Quantitative binding of MOG-IgG toMOG isoforms α1-3 (upper panel) and β1-3 (lower panel) for all
378 samples according to their MOG-IgG serostatus (202 positive and 176 negative). Seropositive samples with an aquaporin-4–seronegative non-MS
demyelinating disease typically associated with MOG-IgG (MOGAD, n = 191) are shown as blue violin plots, and seropositive samples from patients with MS
(n = 8) or healthy controls (n = 3) are shown as yellow circles. Seronegative samples are shown as red violin plots. Medians and interquartile ranges are
indicated by the bars within violin plots. CBA = cell-based assay; HCs = healthy controls; IF = immunofluorescence; MOG = myelin oligodendrocyte glyco-
protein; MOG-ecIgD = extracellular MOG immunoglobulin.
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clustering are clearly differentiated in PC1 (all isoforms with
strongest contributions of α1 and β1; 75.3% of variance, Ei-
genvalue 28.7) and PC2 (α2, α3, β2, and β3; 21.2% of vari-
ance, Eigenvalue 8.1) together explaining 96.5% of the total
variance in the data set. The biplot shown in figure 3A indi-
cates the following major groups: negative for PC1 (sero-
negative for MOG-IgG), positive for PC1 but negative for
PC2, and positive for both PC1 and PC2. This separation into
different binding clusters is shown in figure 3 and table 1. The
“negative” cluster (PC1 negative, n = 176) was associated with
MOG-IgG–negative (MOGα1 titer 0-1:80) non-MS,MS, and
HC samples. By contrast, the other binding patterns were
predominantly associated with non-MS and dominated by
either PC1 or PC2: (1) equal binding to α1 and β1 and no
binding to α2, α3, β2, and β3 (pattern α1β1, n = 73), (2) equal
binding to α1 and β1, weaker binding to α2 and α3, and
no binding to β2 and β3 (pattern α1-3β1, n = 64), and (3)
binding to all MOG isoforms (pattern α1-3β1-3, n = 65).
Three representative CBA-IF stainings for samples assigned
to these isoform binding patterns are shown in figure 4.
It is important that these binding patterns were associated
with a non-MS demyelinating disease consistent with
MOGAD when compared with the MOG-IgG–negative pa-
tients and controls (table 1): pattern α1β1 (PPV 94.5%, 95%
CI 86.7 to 97.9), pattern α1-3β1 (PPV 95.3%, 95.3% CI 87.1
to 98.7), and pattern α1-3β1-3 (PPV 93.8%, 93.9% CI 85.2 to
97.6). The proportion of cases with MOGα1 titers ≥1:640
Figure 3 Binding Patterns of Human MOG-IgG to MOG Isoforms α1, α2, α3, β1, β2, and β3
(A) Scatter dot plot showing the principal compo-
nent (PC) scores of all samples and the loading
scores of all MOG isoforms to visualize parame-
ters responsible for clustering. This identified dif-
ferent binding pattern clusters associated with
PC1 (α1 and β1) and/or PC2 (α2, α3, β2, and β3).
Heatmap of the quantitative results (MOG-IgG ti-
ters) for all MOG-IgG–seronegative samples (B) or
MOG-IgG–seropositive samples (C) according to
their MOG isoform binding pattern (negative,
α1β1, α1-3β1, and α1-3β1-3). Each column is an
individual MOG isoform, and each row is an in-
dividual serum sample withMOG isoform binding
patterns indicated on the left. MOG-IgG reactiv-
ities (titer 1:) are shown in different color in-
tensities (legend with the log scale) and clinical
diagnosis of non-MS, MS, and HC. (B) Individual
MOG isoform IgG titers (median with the inter-
quartile range) according to the identified binding
patterns. The cutoff value for MOG-IgG positivity
(α1 1:160) is indicated by the dashed blue line.
(C) Percentage of patientswith clinical diagnosis of
non-MS (MOGAD), MS, and HC according to MOG
isoform binding patterns. HCs = healthy controls;
MOG = myelin oligodendrocyte glycoprotein;
MOGAD = MOG-IgG–associated disorders; MOG-
IgG = serum IgG antibodies against MOG.
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(high-titer MOG-IgG positive) specifically associated with
MOGAD16 was higher in the α1-3β1-3 (74%) than in the α1-
3β1 (58%) or α1β1 (59%) binding patterns.
Furthermore, we analyzed 106 available follow-up samples
of 35 cases (7 α1β1, 15 α1-3β1, and 13 α1-3β1-3) to assess
the temporal stability of these binding patterns. As shown in
figure e-4, links.lww.com/NXI/A498, 3 of the 7 (43%) pa-
tients with α1β1, 10 of the 15 (71%) patients with α1-3β1,
and 9 of the 13 (69%) patients with α1-3β1-3 binding pat-
terns kept their isoform binding pattern. The other patients
converted to α1β1 (3) or α1-3β1 (3), or became seronegative
(7). There was no conversion from α1β1 to α1-3β1-3 or vice
versa.
Associations of Different MOG-IgG Binding
Patterns With Non-MS Clinical Phenotype,
Disease Course, and Neuropathology
Children with a non-MS disease course were more frequently
associated with MOG isoform binding patterns α1β1 and α1-
3β1, whereas adults were more frequently associated with α1-
3β1-3 or seronegative MOG-IgG (table 1). The percentage of
females was comparable between binding patterns. Further-
more, the percentage of patients with different clinical pre-
sentations of a non-MS demyelinating disease (cerebral,
opticospinal, or mixed presentation) or monophasic or re-
current course at the last follow-up was comparable in all 3
MOG isoform binding patterns. Moreover, there was no as-
sociation of IgG titers or seropositivity against the individual
Table 1 Comparison of Demographic and Clinical Data of All Patients and Controls According to Their MOG Isoform
Binding Patterns
Negative (n = 176) α1β1 (n = 73) α1-3β1 (n = 64) α1-3β1-3 (n = 65) p Valuea
MOGα1 (1:)b 0 (0–20) 640 (320–1,280)c 640 (320–1,280)c 1,280 (320–2,560)c <0.001
MOGα2 (1:)b 0 (0–0) 0 (0–0) 20 (0–40)c,d 640 (160–1,280)c,d,e <0.001
MOGα3 (1:)b 0 (0–0) 0 (0–0) 160 (40–160)c,d 1,280 (640–2,560)c,d,e <0.001
MOGβ1 (1:)b 0 (0–20) 640 (320–1,280)c 640 (320–1,280)c 640 (320–2,560)c <0.001
MOGβ2 (1:)b 0 (0–0) 0 (0–0) 0 (0–0) 160 (40–320)c,d,e <0.001
MOGβ3 (1:)b 0 (0–0) 0 (0–0) 0 (0–20) 320 (80–640)c,d,e <0.001
Age (y)b 36.2 (18.2–45.6) 17.5 (7.2–42.0)c 18.1 (6.0–36.9)c 23.5 (8.7–43.8) <0.001
Children (<18 y)f,g 19.9% (14.7–26.4) 52.1% (40.8–63.1)c 50.0% (38.1–61.9)c 40.0% (29.0–52.1)c <0.001
Femalesf,g 62.6% (54.5–70.0) 46.6% (35.6–57.9) 50.0% (38.1–61.9) 52.3% (40.4–64.0) ns
Clinical diagnosisf,g
Non-MS (MOGAD) 13.1% (8.9–18.8) 94.5% (86.7–97.8)c 95.3% (87.1–89.7)c 93.8% (85.2–97.6)c <0.001
MS 31.8% (25.4–39.0) 5.5% (2.2–13.2) 1.6% (0.1–8.3) 4.6% (1.3–12.7)
HC 55.1% (47.7–62.3) 0.0% (0.0–5.0) 3.1% (0.6–10.7) 1.5% (0.1–8.2)
Clinical phenotypef,g
Cerebralh 56.5% (36.8–74.4) 30.4% (20.9–42.1) 31.1% (20.9–43.6) 29.5% (19.6–41.9) ns
Opticospinali 43.5% (25.6–63.2) 65.2% (53.4–75.4) 63.9% (51.4–74.8) 62.3% (49.7–73.4)
Mixedj 0.0% (0.0–14.3) 4.3% (1.2–12.0) 4.9% (1.3–13.5) 8.2% (3.6–17.8)
Disease coursef,g
Monophasic 87.0% (67.9–95.5) 55.1% (43.4–66.2) 49.2% (37.1–61.4) 57.4% (44.9–69.0) ns
Recurrent 13.0% (4.5–32.1) 44.9% (33.8–56.6) 50.8% (38.6–62.9) 42.6% (31.0–55.1)
Abbreviations: ADEM = acute disseminated encephalomyelitis; MOG = myelin oligodendrocyte glycoprotein; MOGAD = MOG-IgG–associated disorders;
NMOSD = neuromyelitis optica spectrum disorder.
a p values were adjusted for 12 comparisons using Bonferroni’s correction.
b Median (interquartile range), groups were statistically compared using the Kruskal-Wallis test.
c Significantly different from the MOG-IgG–negative group.
d Significantly different from the αβ group.
e Significantly different from the α1-3β1 group.
f Percentage with 95% CI, groups were statistically compared using the χ2 test.
g Only patients with an aquaporin-4–seronegative non-MS demyelinating disease typically associated with MOG-IgG (MOGAD).
h ADEM, MDEM, brainstem encephalitis, or encephalitis.
i Isolated optic neuritis, myelitis, brainstem syndrome, or a combination thereof (including NMOSD).
j ADEMON or opticospinal presentation with cerebral involvement.
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MOG isoforms with demographic or clinical parameters
(tables e-4 and e-5, links.lww.com/NXI/A498).
Finally, we analyzed the neuropathologic features at disease/
relapse onset and follow-up in the 6 cases with available bi-
opsies and/or autopsies (figure e-5, links.lww.com/NXI/
A498). One of these cases (perivenous demyelination) had
α1β1 antibodies, 1 had the α1-3β1 binding pattern (peri-
venous demyelination, conversion to low-titer MOG-IgG at
follow-up), and 4 had the α1-3β1-3 binding pattern (1 with
perivenous and 3 with confluent demyelination, one of them
with intrathecal MOG-IgG).
MOG-IgG Binding Patterns to Different
Isoforms Are Associated With a Differential
Recognition of MOG Epitopes
We performed a number of additional experiments (reactivity to
several mutations in the extracellular Ig domain of MOGα1,
competitive binding experiments with soluble MOG-ecIgD, re-
activity in CBA-FACS and ELISA, reactivity to fixed MOG
expressing cells, and reactivity to human, mouse, and rat MOG in
brain tissue) to elucidate the molecular mechanisms underlying
the 3 different MOG isoform binding patterns in a subset of
samples. Figure 5A shows the differential binding to human
MOGα1mutants, as well as mouse and rat MOG observed in the
3 MOG-IgG binding patterns in relation to MOGα1. The P42S
and E64K mutations strongly affected MOG-IgG binding in all 3
binding patterns, with the strongest reduction seen in the α1β1
pattern. TheN31Q,A75S, R86Q, andH103A+S104Emutations
had comparable effects in all binding patterns. Binding to mouse
and rat MOG was reduced in all 3 isoform binding patterns.
Next, we analyzedwhether the binding to differentMOG isoforms
can be inhibited by competition with increasing concentrations
(0, 1.6, 3.2, and 9.6 μM)of soluble humanMOG-ecIgD in aCBA-
FACS competitive binding assay. As shown in figure 5B, addition
of solubleMOG-ecIgDwas able to reduce the binding toMOGα1
in the α1-3β1-3 pattern comparable with the monoclonal MOG
antibody 8-18-C5, but not in pattern α1β1. Furthermore, pattern
α1-3β1-3 also had similar IC50 and affinities (0–10 μM, figure
5C). By contrast, antibodies of pattern α1β1 did not seem to bind
to the solubleMOG-ecIgD. Of interest, pattern α1-3β1 appears to
hold a position between the 2. Because median MOG-IgG titers
were comparable (1:640 for all 3 binding patterns), we can exclude
an antibody concentration effect. Similar findings were obtained
using an MOG-IgG ELISA in which α1-3β1-3 antibodies showed
better binding than the other patterns (figure 5D). By contrast, we
observednodifferences for reactivity inCBA-FACS,fixedCBA-IF,
and antibody binding to human, mouse, or rat myelin.
Discussion
Our results show that the strongest MOG-IgG responses are
directed against the longest MOG isoforms α1 and β1,
whereas the shorter isoforms α2, α3, β2, and β3 are less
Figure 4 Representative MOG Isoform CBA-IF Stainings
Representative live CBA-IF serum
stainings for the 3 identified MOG
isoform antibody binding patterns
(A, α1β1; B, α1-3β1; C, α1-3β1-3). Only
specific antibody (red) and overlay
images (MOG-transfected cells are
shown in green) were used to reduce
image size (20× magnification). CBA =
cell-based assay; IF = immunofluo-
rescence; MOG = myelin oligoden-
drocyte glycoprotein.
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frequently recognized. Using PCA, we could confirm 3 dis-
tinct MOG isoform binding patterns specific for patients
with MOG-IgG–associated non-MS demyelinating dis-
ease (MOGAD): (1) isolated binding to MOG α1 and β1
only (α1β1), (2) a mixed binding pattern with dominant
recognition of α1 and β1 and at least 1 additional alpha MOG
isoform (α1-3β1), and (3) binding to all MOG isoforms (α1-3
β1-3). Recently, we demonstrated that high-titer positive
MOG-IgG (MOGα1 ≥1:640) are consistently positive in all
live CBAs and specific for non-MS demyelinating disease,
whereas low-titer positive MOG-IgG (MOGα1 1:160–1:320)
are more frequently discordant and sometimes also found in
Figure 5MOG-IgG Binding Patterns to Different Isoforms are Associated With a Differential Recognition of MOG Epitopes
(A) Binding of MOG-IgG to the human MOGα1
mutants N31Q, P42S, E64K, A75S, R86Q, and
H103A + S104E (103/104) and to mouse and rat
MOG according to their MOG isoform binding
patterns (α1β1, n = 64; α1-3β1, n = 43; α1-3β1-3,
n = 46). The median differences compared to
wild-type MOGα1 are shown as symbols with
interquartile ranges (error bars). (B) Competition
of binding to MOGα1 in a CBA-FACS assay by
soluble MOG-ecIgD added in increasing concen-
trations (0, 1.6, 3.2, and 9.6 μM) for the 3 MOG
isoform binding patterns (α1β1, n = 10; α1-3β1,
n = 5; α1-3β1-3, n = 8) and for monoclonal anti-
body 8-18-C5 (dashed line). Squares indicate the
median percentage bound, error bars indicate
the interquartile ranges, and the value used for
the calculation of IC50 (50% binding) is indicated
by the dotted line. Groups were statistically
compared using repeated measures 2-way
analysis of variance. (C) IC50 values for the com-
petition of binding to MOGα1 in a CBA-FACS as-
say by soluble MOG-ecIgD according to MOG
isoform binding patterns (α1β1, n = 10; α1-3β1, n
= 5; α1-3β1-3, n = 8). Individual data points are
shown by scatter dots, and medians and inter-
quartile ranges are indicated by lines and error
bars. The IC50 value for monoclonal antibody 8-
18-C5 is indicated by the dashed line. (D) Binding
of human MOG-IgG according to the 3 MOG
isoform binding patterns to human, mouse, and
rat myelin in brain sections, as well as in ELISA
(human MOG Ig domain), CBA-FACS (human
MOGα1), and a commercial fixed CBA-IF (human
MOGX11). The percentages of myelin/MOG-
IgG–positive samples are shown as bars with
95% CI (error bars). CBA = cell-based assay; FACS
= fluorescence-activated cell sorting; IF = immu-
nofluorescence; MOG = myelin oligodendrocyte
glycoprotein; MOGAD = MOG-IgG–associated
disorders; MOG-ecIgD = extracellular MOG im-
munoglobulin domain; MOG-IgG = serum IgG
antibodies against MOG.
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patients with MS and HCs.16 This observation is also seen in
our study with MOG-IgG–positive MS and HC cases found
only in the low-titer positive group present in all 3 binding
patterns. However, MOG-IgG seropositivity in MS and HCs
in our study was overrepresented compared with previous
studies.1
The recognition of different MOG isoforms by MOG-IgG is
not associated with relevant differences in clinical presentations,
disease course, or neuropathology. Because our study has sev-
eral limitations such as its retrospective design, the heteroge-
nous observation period, andmissing information on treatment,
this needs further investigation in a prospective study. However,
demographic and clinical characteristics of our study population
are consistent with previous reports.1,2,5,6,9,12,22 Our results in-
dicate that α1β1 and α1-3β1 MOG-IgG could be more com-
mon in children and α1-3β1-3 MOG-IgG in adults. This
observation is consistent with previous findings showing a
dominant expression of the isoforms MOG α1 and β1 in the
human brain, and especially in early development, only these 2
isoforms are detected.28,29
We used a number of additional immunologic investigations
to clarify our findings. Only MOG-IgG of the α1-3β1-3, but
not the α1β1, binding pattern also bound to soluble MOG-
ecIgD with high affinity (20 μM–10 nM), which might explain
why immunoprecipitation assays found MOG-IgG less fre-
quently than CBAs25,34 and why attempts to isolate human
MOG-IgG using affinity binding to MOG-ecIgD were only
partly successful.21,23 This result is surprising because all
MOG-IgG presumably bind to epitopes in the extracellular Ig
domain, and therefore, they should compete similarly with
MOG-ecIgG. Additional studies are now needed to elucidate
the underlying molecular mechanisms of this finding. Fur-
thermore, the fact that only a subset of human MOG-IgG
(those of MOG α1-3β1-3 binding pattern) was reactive in
MOG ELISA may explain discrepancies found in the
literature.16,21,25,35 Finally, all 3 MOG isoform binding pat-
terns show different sensitivities to mutations in the extra-
cellular MOG Ig domain: whereas all patterns were sensitive
to the P42S mutation associated with an immunodominant
MOG epitope18,21,23,32 and the E64K mutation in the C0D
loop,36-38 this effect was even more pronounced in the α1β1
binding pattern. Because the α1-3β1 pattern shares many
features with both of the other 2 patterns, it possibly repre-
sents a mixture of the other patterns present in polyclonal
human serum samples. Further work is now necessary to
define the molecular targets of antibodies associated with the
identified MOG isoform binding patterns. However, it is a
limitation of our study that we were not able to perform these
experiments with all samples because of limited availability of
samples and reagents.
Our data indicate that these antibody binding patterns are
associated with clear structural differences, and therefore, it
seems very likely that they represent different antibody
clones. The observed MOG isoform binding patterns could
be explained by the differential recognition of MOG dimers
or multimers caused by clustering of MOG isoforms.37 This
explanation is supported by a recent study demonstrating
that the second hydrophobic domain of MOG (only pre-
sent in α1 and β1) enhanced the recognition of the extra-
cellular part of MOG by human MOG-IgG.39 Moreover,
MOG-IgG frommost patients may require bivalent binding
to MOG dimers, whereas a smaller subset of MOG-IgG
shows monovalent binding to monomers such as the 8-18-
C5 monoclonal antibody.
To conclude, our novel finding of differential MOG isoform
binding patterns could explain previous discrepant reports
and instruct future studies to improve and refine MOG-IgG
antibody assays.
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